Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus obinutuzumab in previously untreated CLL or SLL
2023-504647-14-00Phase 2Authorised
- Sponsor
- Fundación PETHEMA
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zanubrutinib and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Complete response rate with undetectable minimal residual disease. Planned start Jul 2024; status: authorised.
02
Drugs
zanubrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-504647-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504647-14-00.